4-(N-(Butylcarbamoyl)sulfamoyl)benzoic acid
4-(N-(Butylcarbamoyl)sulfamoyl)benzoic acid structure
|
Common Name | 4-(N-(Butylcarbamoyl)sulfamoyl)benzoic acid | ||
|---|---|---|---|---|
| CAS Number | 2224-10-4 | Molecular Weight | 300.33100 | |
| Density | 1.337g/cm3 | Boiling Point | N/A | |
| Molecular Formula | C12H16N2O5S | Melting Point | 210-212ºC | |
| MSDS | USA | Flash Point | N/A | |
| Symbol |
GHS05 |
Signal Word | Danger | |
|
Liquid chromatography/tandem mass spectrometry method for simultaneous evaluation of activities of five cytochrome P450s using a five-drug cocktail and application to cytochrome P450 phenotyping studies in rats.
J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 871(1) , 78-89, (2008) A reliable liquid chromatography/tandem mass spectrometry has been developed for simultaneous evaluation of the activities of five cytochrome P450s (CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A) in rat plasma and urine. The five-specific probe substrates/metabo... |
|
|
Cytochrome P450 2C9 phenotyping using low-dose tolbutamide.
Eur. J. Clin. Pharmacol. 60(3) , 165-71, (2004) The hypoglycaemic drug tolbutamide is used for assessment of CYP2C9 activity in vivo. However, therapeutically active doses of 500 mg bear the risk of hypoglycaemia, and a tolbutamide-derived parameter based on a single plasma or urine concentration reflectin... |
|
|
Quantitative determination of tolbutamide and its metabolites in human plasma and urine by high-performance liquid chromatography and UV detection.
Ther. Drug Monit. 21(6) , 664-71, (1999) An isocratic, high-performance liquid chromatography method has been developed for simultaneous determination of the oral antidiabetic tolbutamide and two of its metabolites, 4-hydroxytolbutamide and carboxytolbutamide, in human plasma and urine. The method w... |
|
|
Inhibition of tolbutamide elimination by cimetidine but not ranitidine.
J. Clin. Pharmacol. 26(5) , 372-7, (1986) This study was designed to compare the effects of equivalent therapeutic doses of two H2 antagonists, cimetidine and ranitidine, on tolbutamide pharmacokinetics. Twelve healthy men were given a 1-g oral dose of tolbutamide on three occasions. Subjects were ra... |
|
|
Pharmacokinetics of tolbutamide in ethnic Chinese.
Br. J. Clin. Pharmacol. 47(2) , 151-6, (1999) Ethnic differences in drug disposition have been described for many drugs. Despite the widespread use of tolbutamide in Asian populations, the pharmacokinetics of tolbutamide, a CYP2C9 substrate, have not been described in ethnic Chinese.The pharmacokinetics ... |
|
|
Excretion of tolbutamide metabolites in young and old subjects.
Eur. J. Clin. Pharmacol. 38(5) , 523-4, (1990) Tolbutamide (1 g/70 kg) was administered as a single intravenous dose to 31 healthy, non-smoking, drug-free males between 23 and 87 years old and the total amounts of hydroxy and carboxytolbutamide excreted in 24 h were measured. There was a significant decre... |
|
|
A new aspect of tolbutamide metabolism in the rabbit: the role of 1-butyl-3-(p-formylphenyl)sulphonylurea.
J. Pharm. Pharmacol. 45(3) , 231-3, (1993) We investigated the metabolism of tolbutamide by using synthetic 1-butyl-3-(p-formylphenyl)sulphonylurea (ATB), an intermediate in the metabolic pathway of tolbutamide. ATB (40 mg kg-1) administered intravenously to rabbits was oxidized to 1-butyl-3-(p-carbox... |
|
|
The comparative effects of tolbutamide and the non-hypoglycemic analog carboxytolbutamide on guanylate cyclase activity.
Horm. Metab. Res. 18(1) , 10-3, (1986) Tolbutamide and its non-hypoglycemic analog carboxytolbutamide increased soluble and particulate guanylate cyclase [E.C.4.6.1.2] activity twofold in liver, lung, colon, pancreas, kidney cortex, heart and spleen at a concentration of 1 microM. The ED50 for sti... |
|
|
In vivo effect of clarithromycin on multiple cytochrome P450s.
Drug Metab. Dispos. 29(7) , 1023-8, (2001) The in vivo effects of oral clarithromycin administration on the in vivo activity of cytochrome P450 1A2, 2C9, and 2D6 were determined. The cytochrome P450 probes caffeine (CYP1A2), tolbutamide (CYP2C9), and dextromethorphan (CYP2D6) were administered as an o... |
|
|
In vitro and in vivo characterization of 13 CYP2C9 allelic variants found in Chinese Han population.
Drug Metab. Dispos. 43(4) , 561-9, (2015) Our previous study detected totally 35 CYP2C9 allelic variants in 2127 Chinese subjects, of whom 21 novel alleles were reported for the first time in Chinese populations. The aim of the present study was to characterize the 13 CYP2C9 allelic variants both in ... |